Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Stroke 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Multiple Myeloma 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Hepatocellular 1COVID-19 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × tocilizumab × Clear all
NCT06372574 2024-09-03

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Genentech, Inc.

Phase 1 Withdrawn

Neoplasms, Recurrence

NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡